Seeking Alpha

BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable...

BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable results on testing of its hepatitis C treatment BCX5191. The preclinical study showed that BCX5191 demonstrates high oral bioavailability and is actively transported into the liver.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs